Stock Performance and Market Position
On 2 December 2025, Venus Remedies recorded a notable 5.00% gain in a single trading day, outperforming the Sensex which showed a decline of 0.43%. The stock touched an intraday high of ₹756, approaching its 52-week high of ₹757 by just 1.61%. This recent surge adds to a two-day consecutive gain period, during which the stock has delivered a 7.71% return.
The stock’s performance over longer time frames further highlights its market strength. Over the past month, Venus Remedies has shown a return of 75.19%, significantly outpacing the Sensex’s 1.59% in the same period. The three-month return stands at 64.79%, compared to the Sensex’s 6.38%, while the one-year return is 139.36%, dwarfing the Sensex’s 6.26%. Year-to-date, the stock has recorded a 141.68% return against the Sensex’s 9.13%.
Extending the horizon, Venus Remedies has delivered a 283.03% return over three years and an impressive 440.94% over five years, compared to the Sensex’s 35.63% and 91.11% respectively. Over a decade, the stock has generated a 470.10% return, substantially exceeding the Sensex’s 226.48%.
These figures underscore Venus Remedies’ consistent ability to outperform broader market indices, reflecting strong investor confidence and operational momentum.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Position for Explosive Growth →
Financial Metrics Underpinning the Rise
Venus Remedies’ financial results have demonstrated substantial growth, contributing to the stock’s upward trajectory. The company reported a net profit growth of 473.5% in its September 2025 results, marking a very positive performance. This follows four consecutive quarters of positive results, indicating sustained profitability.
In the latest six-month period, the company’s profit after tax (PAT) stood at ₹29.73 crores, reflecting a growth of 528.54%. Profit before tax excluding other income (PBT less OI) for the quarter was ₹24.78 crores, showing an extraordinary increase of 2073.68%. These figures highlight the company’s operational efficiency and earnings strength.
Return on capital employed (ROCE) for the half-year reached 13.99%, the highest recorded, while return on equity (ROE) is at 10.5%. These returns indicate effective utilisation of capital and shareholder funds.
The company’s valuation metrics also present an attractive picture. Venus Remedies trades at a price-to-book value of 1.7, which is considered fair relative to its peers’ historical valuations. The price-to-earnings-to-growth (PEG) ratio stands at 0.1, reflecting the relationship between its earnings growth and market price.
Technical Indicators and Market Sentiment
From a technical standpoint, Venus Remedies is trading above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning often signals a strong upward momentum in the stock price.
In terms of sector performance, Venus Remedies outperformed the Pharmaceuticals & Biotechnology sector by 2.79% on the day of the latest trading session, reinforcing its relative strength within the industry.
Market Capitalisation and Debt Profile
The company’s market capitalisation grade is noted as 4, reflecting its standing within the market capitalisation spectrum. Notably, Venus Remedies maintains a low debt-to-equity ratio, averaging zero, which suggests a conservative approach to leverage and financial risk.
This low leverage position may contribute to the company’s ability to sustain growth and manage financial obligations effectively.
Get the full story on Venus Remedies ! Our detailed research dives into fundamentals, sector comparison, technical analysis, and valuations for this Pharmaceuticals & Biotechnology micro-cap. Make informed decisions!
- - Full research story
- - Sector comparison done
- - Informed decision support
Long-Term Growth and Market Outperformance
Venus Remedies’ stock has demonstrated remarkable long-term growth, significantly outpacing the broader market indices. Over the past decade, the stock’s return of 470.10% has more than doubled the Sensex’s 226.48%. Similarly, the five-year and three-year returns have exceeded the Sensex by wide margins, underscoring the company’s sustained market outperformance.
In addition to price appreciation, the company’s profit growth over the past year has been substantial at 183%, reinforcing the strong fundamentals behind the stock’s performance.
Considerations on Shareholding Patterns
Despite the company’s size and performance, domestic mutual funds currently hold no stake in Venus Remedies. Given that domestic mutual funds often conduct in-depth research and hold positions based on their assessment of value and risk, this absence may reflect a cautious stance at prevailing price levels or other considerations.
While this factor does not detract from the company’s financial achievements, it is a noteworthy aspect of the stock’s market profile.
Summary
Venus Remedies’ stock reaching an all-time high is a testament to its strong financial results, consistent profit growth, and market resilience. The company’s ability to deliver returns well above market benchmarks over multiple time frames highlights its position as a significant player in the Pharmaceuticals & Biotechnology sector.
With robust earnings growth, attractive valuation metrics, and technical indicators signalling strength, the stock’s milestone reflects a noteworthy chapter in its market journey.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
